Indaptus Therapeutics
INDP
20 hedge funds and large institutions have $55.6M invested in Indaptus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
54% more funds holding
Funds holding: 13 → 20 (+7)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
41% less capital invested
Capital invested by funds: $94.6M → $55.6M (-$39M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.87M |
| 2 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$434K |
| 3 |
Renaissance Technologies
New York
|
+$372K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$294K |
| 5 |
DMK
David M. Knott
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.4M |
| 2 |
NC
Nexthera Capital
New York
|
-$2.47M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$1.79M |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$31K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$31K |
INDP Hedge Fund Activity: Q4 2017 in Review
20 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2017, worth a combined $55.6M — down 41% from $94.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new INDP positions and 3 closed out — a net gain of 7 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.87M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.4M sold.
- 20 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2017, up from 13 in Q3 2017.
- Funds reported $55.6M of Indaptus Therapeutics stock for Q4 2017, down 41% quarter-over-quarter.
- 10 funds opened new Indaptus Therapeutics positions in Q4 2017 and 3 closed out, a net change of +7 holders.
- The largest Indaptus Therapeutics buyer in Q4 2017 was Millennium Management, an estimated $1.87M added.
- The largest Indaptus Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2017.